A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers.
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs HLX 07 (Primary) ; Dexamethasone; Diphenhydramine; Ondansetron; Paracetamol
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Henlius Biotech
- 24 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
- 24 Jan 2017 Status changed from not yet recruiting to recruiting.
- 15 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.